Save
esh.org
Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications
ESH eLearning, Oliver Hermine, 95253
Gene therapy in thalassaemia and sickle cell disease
ESH eLearning, Yves Beuzard, 95014
Bone marrow transplantation in thalassaemia and sickle cell disease, including haploidentical BMT
ESH eLearning, Alina Ferster, 95013
Guidelines for the biological diagnosis of haemoglobinopathies
ESH eLearning, C.L. Harteveld, 95012
Unstable haemoglobins: Physiopathology, clinical and biological diagnosis
ESH eLearning, Patricia Aguilar-Martinez, 95011
Laboratory diagnosis of abnormal haemoglobins, an update - From phenotype to genotype
ESH eLearning, Frederic Cotton, 95016
Sickle cell disease in adults and elderly patients: Emerging complications and management
ESH eLearning, Lucia De Franceschi, 95010
Sickle cell disease (SCD) in children and adolescents
ESH eLearning, Mariane de Montalembert, 95009
Alpha-thalassaemia: new fast test for the molecular diagnosis
ESH eLearning, C.L. Harteveld, 95008
Beta-thalassaemia: from CBC to DNA: methodologies and laboratory diagnosis
ESH eLearning, Patricia Aguilar-Martinez, 95007
Beta-thalassaemia: clinical findings, molecular defects genotype / phenotype relationship
ESH eLearning, Maria Domenica Cappellini, 95005
Recommendations for the recognition of centres of expertise on haemoglobinopathies in Europe
ESH eLearning, Joan-LLuis Vives-Corrons, 95004
Prevention programmes for thalassaemia and sickle cell disease: past and present
ESH eLearning, Michael Angastiniotis, 95003
Prevention of severe forms of haemoglobinopathies: Newmethodologies and procedures
ESH eLearning, Marina Kleanthous, 95001
Neonatal screening for sickle cell disease in European countries: where are we in 2015?
ESH eLearning, BEATRICE GULBIS, 95000
Migrations and haemoglobin disorders: current status in European countries
ESH eLearning, Maria del Mar MANU (Mañú), 94999
Introduction to the course
ESH eLearning, Patricia Aguilar-Martinez, 95252
Communication Skills
ESH eLearning, Session Speakers, 98455
Epidemiology of MDS and environmental factors
ESH eLearning, D. Bowen, 165409
Germline mutations predisposing to MDS
ESH eLearning, Brigitte Schlegelberger, 165410
Myelodysplastic stem cells
ESH eLearning, P. Woll, 165413
Cytogenetics
ESH eLearning, G. Göhring, 165415
Flow Cytometry in the Diagnostic Work-up of Myelodysplastic Syndromes
ESH eLearning, T. Westers, 165417
Molecular Biology
ESH eLearning, T. Haferlach, 165419
Prognosis and risk assessment
ESH eLearning, L. Malcovati, 165421
Predictive factors for response to treatment
ESH eLearning, R. Itzykson, 165423
Pathophysiology and treatment of anaemia in MDS
ESH eLearning, E. Hellström-Lindberg, 165424
Management of MDS with del(5q)
ESH eLearning, M. Jädersten, 165425
High risk MDS
ESH eLearning, L. Ades, 165426
Allogeneic HSCT
ESH eLearning, T. De Witte, 165427
Experimental transplantation approaches
ESH eLearning, N. Kröger, 165428
Apoptosis and erythroid differentiation
ESH eLearning, G. Courtois, 165650
Autophagy and erythroblast maturation
ESH eLearning, V. Betin, 165651
Epidemiology, pathophysiology and treatment of high altitude polycythemia (Monges’s disease)
ESH eLearning, J.P. Richalet, 165652
Large-scale erythroid differentiation using iPS cells
ESH eLearning, L. Douay, 165653
Not so benign haematology: anaemia of the elderly
ESH eLearning, C.N. Roy, 165654
Novel erythropoiesis-stimulating agents: a new era in anaemia management
ESH eLearning, I. Macdougall, 165655
Malaria: pathology and cytoadherence
ESH eLearning, A. Merckx, 165656
Modifier genes in sickle cell disease
ESH eLearning, J. Elion, 165657
Current diagnostics in- and classification of NHL, including demonstration of diagnostic pitfalls
ESH eLearning, A. Rosenwald, 165472
Staging and response evaluation, including the role of PET/CT scanning, including demonstration of pitfalls in imaging
ESH eLearning, M. Hutchings, 165473
Treatment options, including clinical cases, controversies
ESH eLearning, A. Hagenbeek, 165474
Treatment options, including clinical cases, controversies
ESH eLearning, M. Dreyling, 165475
Current diagnostics and staging of MM, including demonstration of diagnostic pitfalls
ESH eLearning, H. Goldschmidt, 165476
Stratification and response evaluation, including demonstration of pitfalls
ESH eLearning, H. Avet-Loiseau, 165477
Treatment options, including clinical cases, controversies
ESH eLearning, M.V. Mateos, 165478
Treatment options, including clinical cases, controversies
ESH eLearning, G. Merlini, 165479
State of the art including methods for graft facilitation
ESH eLearning, H.E. Broxmeyer, 165531
Cord blood subpopulations and reprogrammed cells
ESH eLearning, G. Koegler, 165532
State of the art
ESH eLearning, E.J. Shpall, 165533
Hematopoietic stem cell expansion to overcome non-engraftment
ESH eLearning, J. Wagner, 165534
The present and future challenges of gene therapy for sickle cell disease
ESH eLearning, F. Mavilio, 165535
Biomarker – based personalized medicine
ESH eLearning, S. Paczesny, 165536
Tregs for immune modulation
ESH eLearning, J. Wagner, 165537
Assesment of HLA diversity in Marseille cord blood bank
ESH eLearning, C. Chabannon, 165538
Human cord blood (CB) derived unrestricted somatic stem cells (USSCS) significantly improves survival and wound healing in an animal model of recessive dystrophic epidermolysis bullosa (RDEB)
ESH eLearning, M. Cairo, 165539
Crosstalk between umbilical cord/cord blood endothelial precursors and mesenchymal stromal cells in promoting new blood vessel formation
ESH eLearning, S. Watt, 165540
Treatment of mesenchymal stromal cells with immunosuppressive drugs increases their immunoregulatory potency
ESH eLearning, J. Girdlestone, 165541
The Italian Cord Blood Platelet Gel project
ESH eLearning, P. Rebulla, 165542
Increasing use of hematopoietic stem cell transplantation for ethnic minorities
ESH eLearning, M. Oudshoorn, 165543
Role of non HLA markers for donor selection
ESH eLearning, R. Tamouza, 165544
State of the art
ESH eLearning, E. Baudoux, 165545
Updating the cord blood unit inventory to meet current needs
ESH eLearning, S. Querol, 165546
Role of registries to analyze outcomes data – Eurocord – Netcord
ESH eLearning, V. Rocha, 165547
Sickle cell disease global perspective
ESH eLearning, E. Gluckman, 165548
Is sickle cell disease an autonomic nervous system disorder: what triggers the transition from steady state to crisis?
ESH eLearning, T. Coates, 165549
Haplo-identical related hematopoietic stem cell transplant for sickle cell disease
ESH eLearning, R. Jones, 165550
Epidemiology and treatment of sickle cell in Senegal including hydroxycarbamide, transfusions and chelation in children
ESH eLearning, I. Diagne, 165551
State of the art
ESH eLearning, J. Wagner, 165552
Results of single and double cord blood in adult malignancies: cost efficiency study
ESH eLearning, A. Ruggeri, 165553
Conditioning for cord blood transplant
ESH eLearning, G. Sanz, 165554
Cord blood transplant in children with non malignant disease
ESH eLearning, E. Gluckman, 165555
Cord blood transplantation for adults: what have we learned
ESH eLearning, D. Weisdorf, 165556
Unrelated donor umbilical cord blood transplantation (UCBT) for hemoglobinopathy using reduced intensity conditioning (RIC)
ESH eLearning, A. Abraham, 165557
Outcome analysis of unrelated cord blood transplantation in Korea
ESH eLearning, Y.H. Lee, 165558
Allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of high risk hemoglobinopathy patients lacking a fully HLA-matched sibling donor using a novel myeloablative, reduced toxicity conditioning regimen
ESH eLearning, S. Kharbanda, 165559
Haplo versus cord blood: pros cord blood
ESH eLearning, J. Wagner, 165560
Algorythm of donor choice
ESH eLearning, K. Ballen, 165561
The RTN Policy: a comprehensive algorythm of the allogeneic hematopoietic stem cell transplant for adults with hematological malignancies
ESH eLearning, W. Arcese, 165562
Networks, research tools and cooperation: the example of network research on sickle cell disease in Central Africa
ESH eLearning, L. Tshilolo, 165563
Problems related to the availability of opioids in Africa
ESH eLearning, E. Kafando, 165564
Association for the struggle against sickle cell disease in Niger
ESH eLearning, F. Hima, 165565
Struggle against sickle cell disease Madagascar-France
ESH eLearning, P. Jeannot, 165566
Support association for SCD in Mauritania
ESH eLearning, M. Wane, 165567
Senegalese Association for the struggle against Sickle Cell Disease
ESH eLearning, M. Ndiaye, 165568
Waldenstrom macroglobulinemia
ESH eLearning, Enrica Morra, 38714
Smouldering Myeloma
ESH eLearning, María-Victoria Mateos, 38710
MGUS
ESH eLearning, Shaji Kumar, 38705
Role of Allo
ESH eLearning, Henk Lokhorst, 38707
Role of consolidation / maintenance
ESH eLearning, M Mohty, 38697
Stratification for risk or age
ESH eLearning, Michele Cavo, 38699
Treatment of relapse
ESH eLearning, Michel Delforge, 38701
Treatment of fit elderly patients
ESH eLearning, Antonio Palumbo, 38718
Treatment of younger patients
ESH eLearning, Pieter Sonneveld, 38720
Histone deacetylase
ESH eLearning, Enrique Ocio, 38716
Monoclonal antibodies
ESH eLearning, Sagar LONIAL, 38708
Pomalidomide
ESH eLearning, Thierry Facon, 38702
Carfilzomib
ESH eLearning, Keith Stewart, 38721
MLN9708
ESH eLearning, Roman Hajek, 38703

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings